ARC enrolling for COVID-19 variants vaccine trial
June 23, 2022
ARC Clinical Research is participating in a COVID-19 vaccine study testing an “updated” Pfizer‐BioNTech vaccine targeting specific variants.
Why are COVID-19 clinical trials needed?
“As new variants emerge with unknown risk, such as the latest Omicron, we must continue to research new approaches to ensure that our vaccines can adequately protect against COVID-19,” said Amy B. Siegel, MD, ARC Internal Medicine physician and ARC Clinical Research Principal Investigator. “If evidence emerges that the existing vaccines are less effective against the variants, trials like this one will make us better prepared.”
Volunteers may be eligible to participate if they:
- Are a man or non-pregnant woman 18 years to 85 years old
- Have previously received the BNT162b2 vaccine* (also known as the Pfizer-BioNTech vaccine; 30 μg, two dose regimen) at least 6 months ago
- Have not previously received vaccination for COVID 19
- Have no history of COVID-19 and/or clinical or microbiological evidence of prior infection at screening
- Have no known history of HBV or HIV
- Have no known history of cardiovascular diseases
- Have had no previous allergic reactions to vaccines
There are other requirements for taking part in this clinical study. The study team will discuss these other criteria with you.
ARC Clinical Research is the only site in Central Texas recruiting for the BioNTech clinical trial.
Clinical trial spots are limited!
If you are interested in participating, contact ARC Wilson Parke Clinical Research at 512-225-5931 or click here to learn more about the study and how to enroll in these clinical trials.